Marshall Edwards, Inc. ('MEI') is a pharmaceutical company dedicated to the field of cancer therapy (oncology).

MEI is developing a range of anti-cancer therapies that represents the next generation of oncology drugs - multiple signal transduction regulators (abbreviated as 'MSTR') that reach to the heart of the cancer process.

The source of this new range of drugs is a family of chemicals, discovered by pharmaceutical company Novogen, that act against the fundamentals of the cancer process. Using this single technology platform, MEI is developing a number of drugs with novel actions against a range of different cancer types.

The first of these drugs - phenoxodiol - has advanced to Phase III clinical studies.

Go to Newsroom for the latest announcement and clinical trials for a listing of the current trials.

 

Marshall Edwards Inc. Investment Information

Marshall Edwards Inc.